Behind every sample is a life—a life filled with questions. We help provide answers with our broad menu of over 400 neurology tests, including a full portfolio for Alzheimer’s disease and dementia testing, as well as expansive testing for complex neuroimmunological diseases and other neurological conditions.
The complexity of the neurological system and the absence of a specific clinical presentation make it difficult to know where to look first. In most cases, early detection and prompt therapy can improve patient outcomes.1 We offer a comprehensive neurological testing portfolio, including blood and CSF testing methods, so you can provide the answers and care your patients deserve.
Alzheimer’s disease affects over 6M people in the US2 and may contribute to up to 70% of cases of dementia.3 Quest offers a simple blood test that has been shown to be as effective as PET scans or spinal taps for cerebrospinal fluid testing to assess a patient’s risk of developing Alzheimer’s disease.4
Neuroimmunological diseases are complex. Testing for them shouldn’t be. Quest Advanced® Neurology has expanded offerings for several autoimmune neurological disorders and makes testing more accessible and actionable.
Our neuroimmunology portfolio includes testing for myasthenia gravis, paraneoplastic syndromes, autoimmune encephalitis, neuromyelitis optica, peripheral neuropathy, and multiple sclerosis. Our expansive test menu includes over 40 antibodies and utilizes gold-standard methodologies, such as CBA, RIA, and line blot.5
No matter where each patient is on the diagnostic journey, our complete portfolio of molecular, biochemical, neuroimmunological, cytogenetic, and pharmacogenomic testing can help you and your patient move forward with clarity and confidence.
In the US, 1 in 9 people over 65 has Alzheimer’s disease,6 but there is evidence that early detection and emerging treatments can lessen its impact.
Quest Advanced® Neurology offers a full portfolio of industry-leading diagnostics to assess the risk of Alzheimer’s disease and dementia, whether your patient has a family history or not.
Our neuroimmunology portfolio includes testing for myasthenia gravis, paraneoplastic syndromes, autoimmune encephalitis, neuromyelitis optica, peripheral neuropathy, and multiple sclerosis. Our expansive test menu includes over 40 antibodies and utilizes gold-standard methodologies, such as CBA, RIA, and line blot.5
Research shows that early interventions for ASD and developmental delay can greatly improve a child’s development. We offer AAP guideline-based chromosomal microarray analysis (CMA),7 which has the highest diagnostic yield of any single test for children that is currently available to clinicians.
Quest’s exome testing helps to improve diagnosis, monitoring, and treatment of rare disorders. Exome testing is a well-established tool for diagnosing genetic conditions in situations where no targeted gene testing exists, or when targeted genetic testing has failed to identify the cause of disease.8 Testing includes Proband, Duo, Trio, and Reanalysis.
IEM happen when a genetic defect disrupts the body’s metabolic pathway—causing conditions such as vitamin deficiencies, organic acidemia, and peroxisomal disorders. Because the balance between undertreatment and overtreatment can be precarious, ongoing monitoring is essential. Get the insights you need to manage IEM-derived challenges with our comprehensive genetic test menu and on-demand expertise from genetic counselors.
Identify a patient’s unique stroke risk and take action by assessing their metabolic and cardiovascular risk profile. Quest offers a full range of stroke testing that can help inform care plans and treatment monitoring.
References
Get the very latest news and information from Quest Advanced® Neurology.
About our tests
Get the latest on how Quest Advanced Neurology is providing insights that fuel action.
Quest provides a comprehensive test menu of neurological diagnostic testing, including tests used for epilepsy, dementia, paraneoplastic disorders, multiple sclerosis, and myasthenia gravis.
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services.
Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
